Deals in Depth: August 2009
Executive Summary
The month of August saw pharmaceutical deal values go down. The highest-valued deal was Forest Laboratories' US license to Nycomed's COPD candidate Daxas, which included $100mm up front and $500mm in total milestones. Acquisition volume decreased, across both biopharma and device. Still P&G managed to get $3.1bn in cash by selling its branded drug business to Warner Chilcott. In financings, public offerings continued last month's growth with three transactions in August--from Seattle Genetics, Onyx, and Inspire--netting over $100mm each. In addition, D-Pharm and Cumberland completed the first two pharma IPOs in over a year.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.